We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Apollon Formularies plc | AQSE:APOL | Aquis Stock Exchange | Ordinary Share | IM00BJ0LRD77 | Ordinary shares |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.025 | 0.01 | 0.09 | 0.05 | 0.025 | 0.025 | 0.00 | 15:29:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMAPOL 21 March 2023 Apollon Formularies Plc Apollon agrees a 28 day extension to complete final Due Diligence in order to conclude the proposed Asset sale to Global Hemp Group Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international medical cannabis pharmaceutical company trading on the AQSE Growth Market, that is licenced to research, develop, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision, announces that it has extended the due diligence period by 28 days to Global Hemp Group in order to facilitate final parts of the process which is expected to conclude the previously announced Asset sale by the 28 of April 2023, subject to Shareholder approval at the General Meeting on 11 April 2023. The agreed extension will allow for the final inspection of Apollon's facilities in Jamaica. As part of this process, Stephen Barnhill Jnr has stepped down from his current role as non-board Chief Operating Officer of Apollon to join Global Hemp Group as its interim Chief Executive Officer. He will be instrumental in helping to complete the current process. The directors of the Company accept responsibility for the contents of this announcement. ENDS For additional information, please visit www.apollon.org.uk or contact: Apollon Formularies Tel: +44 771 1980 221 Stene Jacobs stene@apollon.org.uk Peterhouse Capital Limited (Corporate Adviser) Tel: +44 207 220 9795 Guy Miller gm@peterhousecapital.com BlytheRay (Financial PR/IR-London) Tel: +44 207 138 3204 Tim Blythe tim.blythe@blytheweigh.com Megan Ray megan.ray@blytheweigh.com About Apollon and Apollon Jamaica Apollon Formularies plc is an international medical cannabis company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate, perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis in order to treat various illnesses under medical supervision. Apollon and Apollon Jamaica are parties to a Commitment Agreement whereby Apollon is entitled to 95% of Apollon Jamaica's Net Profits, and per a Stock Pledge Agreement that includes Stephen D. Barnhill, M.D., Apollon is to be assigned the entire 49% equity interest of Apollon Jamaica held by Dr. Barnhill, which is the maximum interest in a medical cannabis company allowed to be held by a non-Jamaican, upon the CLA approving the assignment. END
(END) Dow Jones Newswires
March 21, 2023 08:00 ET (12:00 GMT)
1 Year Apollon Formularies Chart |
1 Month Apollon Formularies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions